Allergy Therapeutics plc

OTCPK:AGYT.F Stock Report

Market Cap: US$299.7m

Allergy Therapeutics Management

Management criteria checks 2/4

Allergy Therapeutics' CEO is Manuel Llobet, appointed in Jul 2009, has a tenure of 15.33 years. total yearly compensation is £484.51K, comprised of 67.5% salary and 32.5% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $313.79K. The average tenure of the management team and the board of directors is 8.9 years and 2.5 years respectively.

Key information

Manuel Llobet

Chief executive officer

UK£484.5k

Total compensation

CEO salary percentage67.5%
CEO tenure15.3yrs
CEO ownership0.1%
Management average tenure8.9yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Manuel Llobet's remuneration changed compared to Allergy Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024UK£485kUK£327k

-UK£40m

Mar 31 2024n/an/a

-UK£45m

Dec 31 2023n/an/a

-UK£50m

Sep 30 2023n/an/a

-UK£47m

Jun 30 2023UK£412kUK£342k

-UK£43m

Mar 31 2023n/an/a

-UK£36m

Dec 31 2022n/an/a

-UK£29m

Sep 30 2022n/an/a

-UK£21m

Jun 30 2022UK£665kUK£332k

-UK£14m

Mar 31 2022n/an/a

-UK£10m

Dec 31 2021n/an/a

-UK£5m

Sep 30 2021n/an/a

-UK£1m

Jun 30 2021UK£662kUK£324k

UK£3m

Mar 31 2021n/an/a

UK£5m

Dec 31 2020n/an/a

UK£7m

Sep 30 2020n/an/a

UK£7m

Jun 30 2020UK£614kUK£303k

UK£7m

Mar 31 2020n/an/a

UK£8m

Dec 31 2019n/an/a

UK£8m

Sep 30 2019n/an/a

UK£6m

Jun 30 2019UK£557kUK£295k

UK£3m

Mar 31 2019n/an/a

UK£117k

Dec 31 2018n/an/a

-UK£3m

Sep 30 2018n/an/a

-UK£5m

Jun 30 2018UK£556kUK£286k

-UK£8m

Compensation vs Market: Manuel's total compensation ($USD607.98K) is below average for companies of similar size in the US market ($USD1.48M).

Compensation vs Earnings: Manuel's compensation has increased whilst the company is unprofitable.

CEO

Manuel Llobet (59 yo)

15.3yrs

Tenure

UK£484,506

Compensation

Mr. Manuel Llobet has been the Chief Executive Officer of Allergy Therapeutics plc since July 2009. Mr. Llobet joined Allergy in September 2009 following the successful refinancing by Azure Ventures Limite...

Leadership Team

NamePositionTenureCompensationOwnership
Manuel Llobet
CEO & Executive Director15.3yrsUK£484.51k0.10%
$ 313.8k
Shaun Furlong
CFO & Executive Director1.3yrsUK£207.93k0.000030%
$ 89.9
Beverly Lees
Group Operations Director8.9yrsno datano data
Murray Skinner
Chief Scientific Officer8.9yrsno datano data
Santiago Puig
Business Development Director15.1yrsno datano data
Sue Baker
Head of Human Resourcesno datano datano data
Simon Piggott
Head of Clinical Science7.2yrsno datano data
Alan Bullimore
Head of Communication & Market Developmentno datano datano data
Russell Picket
Group Financial Controllerno datano datano data
Karley Charlotte Cheesman
Company Secretary1.8yrsno datano data
Matthew Heath
Principal Scientistno datano datano data

8.9yrs

Average Tenure

Experienced Management: AGYT.F's management team is seasoned and experienced (8.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Manuel Llobet
CEO & Executive Director15.3yrsUK£484.51k0.10%
$ 313.8k
Shaun Furlong
CFO & Executive Directorless than a yearUK£207.93k0.000030%
$ 89.9
Babatunde Otulana
Senior Independent Director7.4yrsUK£44.50k0.0010%
$ 3.1k
Peter Jensen
Independent Chairman14.1yrsUK£94.00k0.044%
$ 131.8k
Johannes Ring
Member of Scientific Advisory Boardno datano datano data
Hendrik Kees Nolte
Chairman of Scientific Advisory Boardno datano datano data
Anthony Frew
Member of Scientific Advisory Boardno datano datano data
Lawrence Du Buske
Member of Scientific Advisory Boardno datano datano data
Anthony Parker
Non-Executive Director1.9yrsno data0.040%
$ 120.8k
Cheryl Macdiarmid
Independent Non-Executive Director3.1yrsUK£41.13kno data
Zheqing Shen
Non-Executive Director1.9yrsno data0.0019%
$ 5.6k
David William Ball
Independent Non-Executive Directorless than a yearUK£1.85kno data

2.5yrs

Average Tenure

57.5yo

Average Age

Experienced Board: AGYT.F's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.